X07051
A volunteer is injected with a vaccine as he participates in a coronavirus disease (COVID-19) vaccination study at the Research Centers of America, in Hollywood, Florida, U.S., September 24, 2020. REUTERS/Marco Bello - RC2E5J92LTKE
The Food and Drug Administration has issued an emergency authorization for the first COVID-19 vaccine to be deployed in communities across the U.S. but according to recent polling, only 60% of Americans say they would be willing to get inoculated when it s available.
Though the number has increased slightly in the past few months, 21% of Americans still say they do not intend to get the vaccine at all and are “pretty certain” no new information will change their mind.
Posted on 353
Kinder Morgan (NYSE: KMI) announced today that Fayez Sarofim will retire from its board of directors effective December 31, 2020. Mr. Sarofim has served on KMI’s board of directors since 1999.
“Fayez has been a long-standing member of the board, and we appreciate his valuable guidance and advice during his 21 years of service,” said KMI Executive Chairman Rich Kinder. “He has always provided thoughtful and wise suggestions for the betterment of the company. We wish him all the best in his retirement.”
“I have enjoyed working with Rich, the board and the management team during my time serving on the board of directors,” said Mr. Sarofim. “KMI has grown substantially during that period, and I am confident it will continue to be successful in the future.”
Share:
BOSTON, Dec. 14, 2020 (GLOBE NEWSWIRE)
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4 pathway, today announced the appointment of Diego Cadavid, M.D., as Chief Medical Officer. Dr. Cadavid will be responsible for the strategy, direction and execution of the company s clinical development programs. We are very pleased to welcome Diego to our team, said Paula Ragan, Ph.D., President and Chief Executive Officer of X4 Pharmaceuticals. We believe his strong clinical development expertise, in particular with the advancement of small molecules and biologics for the treatment of rare and immunological diseases, will be invaluable as we continue to advance our ongoing clinical programs, including our Phase 3 trial of mavorixafor in WHIM syndrome and our Phase 1b studies in Waldenström s macroglobulinemia and severe congenital neutropenia, as well as our preclinic
Kinder Morgan Announces Fayez Sarofim Retirement From Board of Directors - Press Release digitaljournal.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from digitaljournal.com Daily Mail and Mail on Sunday newspapers.
Early Kinder Morgan Investor Fayez Sarofim to Retire from Board
Fayez Sarofim, one of the original shareholders of Kinder Morgan, is set to retire from the Houston-based pipeline company’s board of directors on Dec. 31.
Hart Energy Staff Your browser does not support the audio element.
Kinder Morgan Inc. announced on Dec. 14 that long-standing board member Fayez Sarofim will retire from its board of directors by the end of the year.
Fayez is a billionaire Houston investment manager and philanthropist who was one of the original shareholders of Kinder Morgan. He has served on the Houston-based pipeline company’s board of directors since 1999.